Sat.Mar 16, 2024 - Fri.Mar 22, 2024

Remove fda-pharmaceutical-companies
article thumbnail

After monumental MASH nod, Madrigal plots $600M stock sale to support Rezdiffra launch

Fierce Pharma

Just a few days ago, Madrigal Pharmaceuticals made history by winning FDA approval for its metabolic dysfunction-associated steatohepatitis (MASH) med Rezdiffra. Now, the company looks to support the upcoming launch by selling shares.

FDA 52
article thumbnail

FDA approves innovative gene therapy for MLD

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved gene therapy Lenmeldy (atidarsagene autotemcel) as the first treatment for children with early-onset metachromatic leukodystrophy (MLD). Deficiency of the enzyme arylsulfatase A (ARSA) and subsequent buildup of sulfatides in the cells is considered to cause MLD, FDA elucidated.

FDA 102